Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | FPR1 | P21462 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299438 | 1.00 | TP53 (0.67) | TP53ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL542855 | 1.00 | TP53 (0.67) | TP53ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL1171070 | 1.00 | TP53 (0.67) | TP53ALDH1A1LMNASMN1; SMN2GAA | |
| N Phthaloyl-L-Threonine SCHEMBL5424529 | 0.87 | TP53 (0.56) | TP53ALDH1A1LMNAGAAPOLB | |
| SCHEMBL27877368 | 0.87 | TP53 (0.53) | TP53ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL13367251 | 0.85 | TP53 (0.62) | TP53ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL25583418 | 0.85 | KDM4E (0.62) | TP53ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL14648862 | 0.84 | TP53 (0.60) | TP53ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL12284244 | 0.84 | TP53 (0.60) | TP53ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL1927731 | 0.84 | TP53 (0.60) | TP53ALDH1A1LMNASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723425-B2 | Pigment compositions with modified ATRP copolymer dispersants | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2010-05-25 | — | — | US | claimed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-3924349-B1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | THE ROSKAMP INST (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-115141138-B | Method for constructing fluoride by decarboxylation of alkyl carboxylic acid | 中山大学 | 2023-11-28 | — | — | CN | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-109153644-B | Small molecules against CEREBLON to enhance effector T cell function | H·李·莫菲特癌症中心研究有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-115141138-A | Method for constructing fluoride by decarboxylation of alkyl carboxylic acid | 中山大学 | 2022-10-04 | — | — | CN | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220081415-A1 | Amino Acid Derivatives for the Treatment of Inflammatory Diseases | THE ROSKAMP INST (US) | 2022-03-17 | — | — | US | disclosed |
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060229407-A1 | Light stabilising polymer dispersants in pigment dispersions | CIBA SPECIALTY CHEMICALS CORP. | 2006-10-12 | — | — | US | disclosed |
| US-20060160940-A1 | Process for intercalating natural or szynthetic clays with block or comb copolymers | CIBA SPECIALTY CHEMICALS CORP. | 2006-07-20 | — | — | US | disclosed |
| US-6849679-B2 | Pigment compositions with modified block copolymer dispersants | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040176426-A1 | FXR modulators | TULARIK, INC. | 2004-09-09 | — | — | US | disclosed |
| US-6777446-B2 | FARNESOID X RECEPTOR; TREATING DISEASES ASSOCIATED WITH ABNORMALLY HIGH OR LOW CHOLESTEROL LEVELS. | TULARIK, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | TULARIK INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002020463-A2 | FXR MODULATORS | TULARIK INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009918-A1 | Chemical Compounds | HPGDS, PTGS1, PTGER1 | TP53 4678/4885ALDH1A1 144/4885LMNA 1339/4885 |
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | NR1H4, NR1H2, NR1H3 | TP53 3212/4885ALDH1A1 2422/4885LMNA 4130/4885 |
| US-20040176426-A1 | FXR modulators | NR1H4, CYP7A1, CYP7B1 | TP53 2798/4885ALDH1A1 1900/4885LMNA 4473/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | TP53 625/4885ALDH1A1 2373/4885LMNA 2916/4885 |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | TP53 387/4885ALDH1A1 4134/4885LMNA 4011/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | TP53 783/4885ALDH1A1 4309/4885LMNA 3945/4885 |
| US-20220081415-A1 | Amino Acid Derivatives for the Treatment of Inflammatory Diseases | NFKBIA, NFRKB, IKBKG | TP53 1553/4885ALDH1A1 4214/4885LMNA 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.